Nuveen California Select Tax-Free Income Portfolio (NXC) Stock Price

13.14 ▼ -0.03 (-0.23%)
Open: 13.14 Vol: 8.79K Day's range: 13.14 - 13.20 Dec 12, 16:00 EST
IEX quote, 15 minutes delayed during trading hours. Login or Signup to see real-time data
Free Stock Screener
Loading chart ...
NXC Technical Analysis
5 mins 30 mins Hourly Daily Weekly
BUY BUY SELL SELL NEUTRAL
  5 mins 30 mins Hourly Daily Weekly
MA5 13.18▲ 13.18▲ 13.18▲ 13.18▼ 13.21▼
MA10 13.18▲ 13.18▲ 13.19▲ 13.21▼ 13.16▼
MA20 13.18▲ 13.18▲ 13.20▼ 13.21▼ 13.03▲
MA50 13.20▼ 13.20▼ 13.21▼ 13.16▼ 12.98▲
MA100 13.22▼ 13.24▼ 13.21▼ 13.02▲ 13.18▼
MA200 13.17▲ 13.10▲ 13.07▲ 12.96▲ 13.30▼
  5 mins 30 mins Hourly Daily Weekly
MACD 0.001▲ 0.002▲ 0.000▼ -0.015▼ 0.024▲
RSI 50.786▲ 49.965▼ 48.801▼ 42.695▼ 54.566▲
STOCH 64.583     59.167     38.542     33.754     56.464    
WILL %R -20.000▲ -50.000     -50.000     -94.118▼ -53.084    
CCI -17.739     -18.706     -31.307     -166.667▼ 44.101    
Latest Filters Detected On NXC
▼ MACD $NXC MACD(12,26,9) Crossed Below Zero Set Alert
MA $NXC Price Crossed Below MA(50) Set Alert
CDL $NXC Doji Candlestick Pattern Detected Set Alert
Nuveen California Select Tax-Free Income Portfolio News
Immix Biopharma Reports Positive ASCO Abstract Results for NXC-201 from NEXICART-2 Trial in Relapsed/Refractory AL Amyloidosis
Thursday, May 22, 2025 01:14 PM
Immix Biopharma has announced positive results from its NEXICART-2 Phase 1/2 clinical trial of the cell therapy NXC-201 for relapsed/refractory AL Amyloidosis, reporting a complete response (CR) rate ...
Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
Thursday, May 22, 2025 09:02 AM
– Updated results with a later data cutoff, including endpoint analysis, will be presented at ASCO by lead investigator Heather Landau, MD, of Memorial Sloan Kettering Cancer Center – Immix’s Phase ...
Raymond James Financial Inc. Invests $275,000 in Nuveen California Select Tax-Free Income Portfolio (NYSE:NXC)
Sunday, May 11, 2025 05:00 PM
Raymond James Financial Inc. purchased a new position in shares of Nuveen California Select Tax-Free Income Portfolio (NYSE:NXC – Free Report) during the fourth quarter, according to the company in ...
NXC historical stock data
date open high low close volume
12/12/25 13.14 13.20 13.14 13.14 8,786
11/12/25 13.15 13.23 13.14 13.17 48,800
10/12/25 13.13 13.20 13.13 13.17 22,900
09/12/25 13.24 13.25 13.17 13.19 23,100
08/12/25 13.20 13.28 13.20 13.25 7,700
05/12/25 13.20 13.25 13.20 13.23 20,500
04/12/25 13.20 13.26 13.20 13.24 17,100
03/12/25 13.16 13.30 13.16 13.21 19,700
02/12/25 13.19 13.24 13.15 13.24 18,500
01/12/25 13.23 13.24 13.18 13.24 17,600
Quote Details
52wk Low:12.41
52wk High:13.446
Vol:8.79K
Avg Vol(3m):359.1K
1Y Chng:+0.31%
1M Chng:-0.68%
Add to Watch List
More Information
Index N/A
Market Cap. 85.00M